ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,502.35
-0.73%
Dow Jones
44,424.25
-0.32%
Gold vs US Dollar
2,771.73
0.00%
Brent Oil
77.625
0.00%
Bitcoin
104,811.70
0.08%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. ETFs
  4. USA
  5. AMEX
  6. Invesco Variable Rate Preferred ETF (VRP)

  7. Invesco Variable Rate Preferred ETF (VRP) News

Invesco Variable Rate Pr... (VRP)

Invesco Variable Rate Preferred ETF
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:VRP
DateTimeSourceHeadlineSymbolCompany
18/02/202107:00GlobeNewswire Inc.Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate UpdateAMEX:VRPInvesco Variable Rate Preferred ETF
02/02/202111:17GlobeNewswire Inc.CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPDAMEX:VRPInvesco Variable Rate Preferred ETF
02/02/202107:00GlobeNewswire Inc.Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPDAMEX:VRPInvesco Variable Rate Preferred ETF
14/01/202107:00GlobeNewswire Inc.Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19AMEX:VRPInvesco Variable Rate Preferred ETF
05/01/202107:00GlobeNewswire Inc.Verona Pharma to Present at H.C. Wainwright Virtual BioConnect ConferenceAMEX:VRPInvesco Variable Rate Preferred ETF
09/11/202007:00GlobeNewswire Inc.Verona Pharma Announces November 2020 Virtual Investor Conference ParticipationAMEX:VRPInvesco Variable Rate Preferred ETF
29/10/202007:00GlobeNewswire Inc.Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020AMEX:VRPInvesco Variable Rate Preferred ETF
22/10/202006:00GlobeNewswire Inc.Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update...AMEX:VRPInvesco Variable Rate Preferred ETF
13/10/202006:00GlobeNewswire Inc.Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020AMEX:VRPInvesco Variable Rate Preferred ETF
08/09/202006:00GlobeNewswire Inc.Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19AMEX:VRPInvesco Variable Rate Preferred ETF
02/09/202006:00GlobeNewswire Inc.Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment ConferenceAMEX:VRPInvesco Variable Rate Preferred ETF
24/08/202006:00GlobeNewswire Inc.Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2...AMEX:VRPInvesco Variable Rate Preferred ETF
19/08/202006:00GlobeNewswire Inc.Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPDAMEX:VRPInvesco Variable Rate Preferred ETF
14/08/202006:00GlobeNewswire Inc.Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020AMEX:VRPInvesco Variable Rate Preferred ETF
03/08/202006:00GlobeNewswire Inc.Verona Pharma Announces August 2020 Virtual Investor Conference ParticipationAMEX:VRPInvesco Variable Rate Preferred ETF
30/07/202006:00GlobeNewswire Inc.Verona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate UpdateAMEX:VRPInvesco Variable Rate Preferred ETF
17/07/202006:00GlobeNewswire Inc.Verona Pharma Raises $200 Million in Oversubscribed Private Placement and SubscriptionAMEX:VRPInvesco Variable Rate Preferred ETF
14/05/202006:00GlobeNewswire Inc.Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANC...AMEX:VRPInvesco Variable Rate Preferred ETF
01/05/202016:12GlobeNewswire Inc.Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic...AMEX:VRPInvesco Variable Rate Preferred ETF
30/04/202006:00GlobeNewswire Inc.Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020AMEX:VRPInvesco Variable Rate Preferred ETF
23/04/202006:00GlobeNewswire Inc.Verona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate UpdateAMEX:VRPInvesco Variable Rate Preferred ETF
16/04/202011:12GlobeNewswire Inc.Verona Pharma plc: Results of AGMAMEX:VRPInvesco Variable Rate Preferred ETF
08/04/202006:00GlobeNewswire Inc.Update on AGM ProcedureAMEX:VRPInvesco Variable Rate Preferred ETF
31/03/202006:00GlobeNewswire Inc.Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPDAMEX:VRPInvesco Variable Rate Preferred ETF
16/03/202017:13GlobeNewswire Inc.2019 Annual Report and Accounts and Notice of AGMAMEX:VRPInvesco Variable Rate Preferred ETF
27/02/202007:00GlobeNewswire Inc.Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate UpdateAMEX:VRPInvesco Variable Rate Preferred ETF
21/02/202007:00GlobeNewswire Inc.Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate UpdateAMEX:VRPInvesco Variable Rate Preferred ETF
14/02/202007:00GlobeNewswire Inc.Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory ResearchAMEX:VRPInvesco Variable Rate Preferred ETF
03/02/202007:00GlobeNewswire Inc.Verona Pharma Announces Senior Management ChangesAMEX:VRPInvesco Variable Rate Preferred ETF
13/01/202005:00GlobeNewswire Inc.Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium T...AMEX:VRPInvesco Variable Rate Preferred ETF
 Showing the most relevant articles for your search:AMEX:VRP

Your Recent History

LSE
TERN
Tern
LSE
VAST
Vast Resources
LSE
QBT
Quantum Blockchain Techn...
LSE
POS
Plexus
LSE
BIRD
Blackbird
LSE
SBTX
Skinbiotherapeutics
LSE
GKP
Gulf Keystone Petroleum
LSE
GEX
Georgina Energy
LSE
BOO
Boohoo
LSE
NEXN
Nexxen
LSE
SYME
Supply@me Capital
LSE
AXL
Arrow Exploration
LSE
PANR
Pantheon Resources
LSE
AAZ
Anglo Asian Mining
LSE
SCLP
Scancell
LSE
LLOY
Lloyds Banking
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads